Proteinuria lowering needs a multifactorial and individualized approach to halt progression of renal disease

Paul E. de Jong; Gerjan Navis

doi:10.1038/ncpneph0963

Proteinuria lowering needs a multifactorial and individualized approach to halt progression of renal disease

Paul E. de Jong^*, Gerjan Navis

^*Corresponding author for this work

Groningen Kidney Center (GKC)

Research output: Contribution to journal › Editorial › Academic › peer-review

5 Citations (Scopus)

Abstract

This Practice Point commentary discusses the implementation of an intensive, multifactorial intervention in patients who had proteinuria >3g/day despite treatment with angiotensin-converting-enzyme inhibitors. In their 'Remission Clinic' in Bergamo, Italy, Ruggenenti et al. implemented an individual titration regimen using ramipril 5-10 mg/day, losartan 50-100 mg/day, verapamil 80-120 mg/day and atorvastatin 10-20 mg/day in successive steps, aiming for a low blood pressure target of

Original language	English
Pages (from-to)	654-655
Number of pages	2
Journal	NATURE CLINICAL PRACTICE NEPHROLOGY
Volume	4
Issue number	12
DOIs	https://doi.org/10.1038/ncpneph0963
Publication status	Published - Dec-2008

Keywords

chronic kidney disease
progression
proteinuria
renoprotective therapy
TITRATION
RISK

Access to Document

10.1038/ncpneph0963

Cite this

@article{d752f05a7e5f4906a94c670416f678f6,

title = "Proteinuria lowering needs a multifactorial and individualized approach to halt progression of renal disease",

abstract = "This Practice Point commentary discusses the implementation of an intensive, multifactorial intervention in patients who had proteinuria >3g/day despite treatment with angiotensin-converting-enzyme inhibitors. In their 'Remission Clinic' in Bergamo, Italy, Ruggenenti et al. implemented an individual titration regimen using ramipril 5-10 mg/day, losartan 50-100 mg/day, verapamil 80-120 mg/day and atorvastatin 10-20 mg/day in successive steps, aiming for a low blood pressure target of",

keywords = "chronic kidney disease, progression, proteinuria, renoprotective therapy, TITRATION, RISK",

author = "{de Jong}, {Paul E.} and Gerjan Navis",

note = "Editorial Material",

year = "2008",

month = dec,

doi = "10.1038/ncpneph0963",

language = "English",

volume = "4",

pages = "654--655",

journal = "NATURE CLINICAL PRACTICE NEPHROLOGY",

issn = "1745-8323",

number = "12",

}

TY - JOUR

T1 - Proteinuria lowering needs a multifactorial and individualized approach to halt progression of renal disease

AU - de Jong, Paul E.

AU - Navis, Gerjan

N1 - Editorial Material

PY - 2008/12

Y1 - 2008/12

N2 - This Practice Point commentary discusses the implementation of an intensive, multifactorial intervention in patients who had proteinuria >3g/day despite treatment with angiotensin-converting-enzyme inhibitors. In their 'Remission Clinic' in Bergamo, Italy, Ruggenenti et al. implemented an individual titration regimen using ramipril 5-10 mg/day, losartan 50-100 mg/day, verapamil 80-120 mg/day and atorvastatin 10-20 mg/day in successive steps, aiming for a low blood pressure target of

AB - This Practice Point commentary discusses the implementation of an intensive, multifactorial intervention in patients who had proteinuria >3g/day despite treatment with angiotensin-converting-enzyme inhibitors. In their 'Remission Clinic' in Bergamo, Italy, Ruggenenti et al. implemented an individual titration regimen using ramipril 5-10 mg/day, losartan 50-100 mg/day, verapamil 80-120 mg/day and atorvastatin 10-20 mg/day in successive steps, aiming for a low blood pressure target of

KW - chronic kidney disease

KW - progression

KW - proteinuria

KW - renoprotective therapy

KW - TITRATION

KW - RISK

U2 - 10.1038/ncpneph0963

DO - 10.1038/ncpneph0963

M3 - Editorial

VL - 4

SP - 654

EP - 655

JO - NATURE CLINICAL PRACTICE NEPHROLOGY

JF - NATURE CLINICAL PRACTICE NEPHROLOGY

SN - 1745-8323

IS - 12

ER -